We caught up with Lexeo Therapeutics’ Manny Otero, Ph.D., and Sandi See Tai, MD, to explore strategies to advance gene therapies.
- Immunology's Next Frontier: High-Risk, High-Reward Innovations From EULAR 2025
- Unlocking Value In Biopharma Operations: A C-Suite Call To Action
- Audit Trail Compliance And What To Look For In Mitigation Software
- Bridging The Disconnect: Commercial Clarity And Communication Will Define The Future Of CGT CDMOs
- The New Clinical Packaging Paradigm: Differentiation And Decentralization
- June 2025 — CDMO Opportunities And Threats Report
- Process Validation: Optimizing Operational Excellence In Pharma And Medical Devices
- 7 New MHRA Guidances To Help You With Decentralized Manufacturing For Cell And Gene Therapies
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Digital Biomanufacturing, Now: From Digital Dreamer To Digital Doer
Discover how digital biomanufacturing is revolutionizing drug production by exploring strategies for integrating digital technologies to enhance efficiency, reliability, and innovation in bioprocessing workflows.
-
A Streamlined Biopharmaceutical Isolator Solution
This custom-designed, eight-foot isolator helped a client meet their decontamination needs, maintaining ISO-5 sterile conditions while decreasing turn-around time for filling small batches.
-
Addressing The Challenges In Lentivirus Harvest Clarification
Traditional depth filtration struggles with lentiviral harvest clarification, leading to low yields and high costs. However, single-use centrifugation offers a promising alternative.
-
Cystic Fibrosis: Global Clinical Trial Landscape (2024)
Gain valuable insights on patient enrollment, site selection, and navigating global regulatory landscapes tailored to rare diseases, thus propelling forward CF research and treatment.
-
Eliminating Antibiotic Resistance Gene Transfer Risks In CGTs
Learn about the drawbacks of antibiotic resistance that can cause side effects in patients and how an antibiotic-free approach can ease the burden of regulatory compliance and accelerate development.
-
Using Automated Spinoculation For CAR T Cell Lentiviral Transduction
There is a growing demand for closed and automated lentiviral transduction steps in CAR T cell therapy workflows. Learn about a potential solution to address this unmet need.
-
The Key To Viral Vector Success
Establishing a robust and scalable viral vector process requires a multidisciplinary approach that incorporates expertise in foundational science, analytics, and biomanufacturing.
-
Exploring Perfusion Technology For Virus Manufacturing Process Intensification
Perfusion cell culture technology supports high cell densities and product yields for viral vaccine manufacturing, offering a reliable way to produce high-quality cells at a commercial scale.
-
Manufacturing Challenges With High Concentration Biologics
Explore key process operations, some of the challenges in manufacturing high-concentration biologics, and factors to consider for process optimization.
-
Prevent The Risk Of Cross-Contamination With Microbial Colony Pickers
Explore a microbial colony picker that streamlines lab workflows to ensure rapid and accurate genetic library screening. Key features include UV sanitization, pin washing, and halogen drying, which meets GMP standards.
NEWSLETTER ARCHIVE
- 07.12.25 -- Cell & Gene Best Of June
- 07.11.25 -- What Global Survey Says About Scant Patient Access To CAR-T Therapy
- 07.10.25 -- Lessons In Automation With Roswell Park Comprehensive Cancer Center's Christopher Choi, Ph.D.
- 07.09.25 -- Take a look at our useful PUPSIT overview and implementation resources.
- 07.09.25 -- Rethinking Academic Translation In CGT: Inside The RISE Framework At Mass General Brigham

- Inside AviadoBio And Astellas's Shared Mission To Bring Gene Therapy To Patients With FTD-GRN
- Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More
- Rethinking Academic Translation In CGT: Inside The RISE Framework At Mass General Brigham
- The Promise Of Focused Ultrasound For AAV Gene Therapy Delivery
- Unlocking The Potential Of iPSC Therapies In Regenerative Medicine
CELL AND GENE CONTENT COLLECTIONS

While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections